Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma

Dedifferentiated liposarcoma (DDLPS) is a highly malignant sarcoma characterized by the co-amplification of <i>MDM2</i> and <i>CDK4</i>. Although systemic chemotherapy is recommended for unresectable or metastatic cases, DDLPS is insensitive to conventional chemotherapy, lead...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ryuto Tsuchiya, Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Takuya Ono, Taro Akiyama, Takeshi Hirose, Shintaro Iwata, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	sarcoma liposarcoma dedifferentiated liposarcoma patient-derived cell line Medicine R
Acceso en línea:	https://doaj.org/article/b4a44e17c2814987a7485cbc5da3bd38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4a44e17c2814987a7485cbc5da3bd38
record_format	dspace
spelling	oai:doaj.org-article:b4a44e17c2814987a7485cbc5da3bd382021-11-25T18:06:55ZEstablishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma10.3390/jpm111110752075-4426https://doaj.org/article/b4a44e17c2814987a7485cbc5da3bd382021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1075https://doaj.org/toc/2075-4426Dedifferentiated liposarcoma (DDLPS) is a highly malignant sarcoma characterized by the co-amplification of <i>MDM2</i> and <i>CDK4</i>. Although systemic chemotherapy is recommended for unresectable or metastatic cases, DDLPS is insensitive to conventional chemotherapy, leading to an unfavorable prognosis. Therefore, novel treatment methods are urgently required. Patient-derived cell lines are essential in preclinical studies. Recently, large-scale screening studies using a number of cell lines have been actively conducted for the development of new therapeutic drugs. However, the DDLPS cell line cannot be obtained from public cell banks owing to its rarity, hindering screening studies. As such, novel DDLPS cell lines need to be established. Accordingly, this study aimed to establish a novel DDLPS cell line from surgical specimens. The cell line was named NCC-DDLPS4-C1. NCC-DDLPS4-C1 cells retained copy number alterations corresponding to the original tumors. Further, the cells demonstrated constant growth, spheroid formation, and equivalent invasiveness to MG63 osteosarcoma cells. We also conducted drug screening and integrated the results with those of the previously reported DDLPS cell lines. Consequently, we identified the histone deacetylase inhibitor romidepsin as a novel candidate drug. In conclusion, the NCC-DDLPS4-C1 cell line is a useful tool for the basic study of DDLPS.Ryuto TsuchiyaYuki YoshimatsuRei NoguchiYooksil SinTakuya OnoTaro AkiyamaTakeshi HiroseShintaro IwataAkihiko YoshidaSeiji OhtoriAkira KawaiTadashi KondoMDPI AGarticlesarcomaliposarcomadedifferentiated liposarcomapatient-derived cell lineMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1075, p 1075 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sarcoma liposarcoma dedifferentiated liposarcoma patient-derived cell line Medicine R
spellingShingle	sarcoma liposarcoma dedifferentiated liposarcoma patient-derived cell line Medicine R Ryuto Tsuchiya Yuki Yoshimatsu Rei Noguchi Yooksil Sin Takuya Ono Taro Akiyama Takeshi Hirose Shintaro Iwata Akihiko Yoshida Seiji Ohtori Akira Kawai Tadashi Kondo Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
description	Dedifferentiated liposarcoma (DDLPS) is a highly malignant sarcoma characterized by the co-amplification of <i>MDM2</i> and <i>CDK4</i>. Although systemic chemotherapy is recommended for unresectable or metastatic cases, DDLPS is insensitive to conventional chemotherapy, leading to an unfavorable prognosis. Therefore, novel treatment methods are urgently required. Patient-derived cell lines are essential in preclinical studies. Recently, large-scale screening studies using a number of cell lines have been actively conducted for the development of new therapeutic drugs. However, the DDLPS cell line cannot be obtained from public cell banks owing to its rarity, hindering screening studies. As such, novel DDLPS cell lines need to be established. Accordingly, this study aimed to establish a novel DDLPS cell line from surgical specimens. The cell line was named NCC-DDLPS4-C1. NCC-DDLPS4-C1 cells retained copy number alterations corresponding to the original tumors. Further, the cells demonstrated constant growth, spheroid formation, and equivalent invasiveness to MG63 osteosarcoma cells. We also conducted drug screening and integrated the results with those of the previously reported DDLPS cell lines. Consequently, we identified the histone deacetylase inhibitor romidepsin as a novel candidate drug. In conclusion, the NCC-DDLPS4-C1 cell line is a useful tool for the basic study of DDLPS.
format	article
author	Ryuto Tsuchiya Yuki Yoshimatsu Rei Noguchi Yooksil Sin Takuya Ono Taro Akiyama Takeshi Hirose Shintaro Iwata Akihiko Yoshida Seiji Ohtori Akira Kawai Tadashi Kondo
author_facet	Ryuto Tsuchiya Yuki Yoshimatsu Rei Noguchi Yooksil Sin Takuya Ono Taro Akiyama Takeshi Hirose Shintaro Iwata Akihiko Yoshida Seiji Ohtori Akira Kawai Tadashi Kondo
author_sort	Ryuto Tsuchiya
title	Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
title_short	Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
title_full	Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
title_fullStr	Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
title_full_unstemmed	Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
title_sort	establishment and characterization of ncc-ddlps4-c1: a novel patient-derived cell line of dedifferentiated liposarcoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b4a44e17c2814987a7485cbc5da3bd38
work_keys_str_mv	AT ryutotsuchiya establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT yukiyoshimatsu establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT reinoguchi establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT yooksilsin establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT takuyaono establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT taroakiyama establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT takeshihirose establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT shintaroiwata establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT akihikoyoshida establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT seijiohtori establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT akirakawai establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma AT tadashikondo establishmentandcharacterizationofnccddlps4c1anovelpatientderivedcelllineofdedifferentiatedliposarcoma
_version_	1718411637528985600

Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma

Ejemplares similares